Found: 30
Select item for more details and to access through your institution.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 19, p. 3344, doi. 10.1002/cncr.35384
- By:
- Publication type:
- Article
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1762, doi. 10.1002/ajh.27073
- By:
- Publication type:
- Article
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1419, doi. 10.1002/ajh.26686
- By:
- Publication type:
- Article
Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia.
- Published in:
- Bulletin of Mathematical Biology, 2018, v. 80, n. 5, p. 1084, doi. 10.1007/s11538-017-0272-7
- By:
- Publication type:
- Article
ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.233
- By:
- Publication type:
- Article
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S222, doi. 10.1016/j.clml.2018.07.092
- By:
- Publication type:
- Article
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S307, doi. 10.1016/j.clml.2017.07.105
- By:
- Publication type:
- Article
Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 584, doi. 10.1016/j.clml.2013.03.020
- By:
- Publication type:
- Article
Deciphering the internal complexity of living cells with quantitative phase microscopy: a multiscale approach.
- Published in:
- Journal of Biomedical Optics, 2015, v. 20, n. 9, p. 096005-1, doi. 10.1117/1.JBO.20.9.096005
- By:
- Publication type:
- Article
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Quantitative and functional analyses of CD4.
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 1, p. 139, doi. 10.1111/j.1365-2141.2010.08453.x
- By:
- Publication type:
- Article
Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 11, p. 5173, doi. 10.1002/cam4.2410
- By:
- Publication type:
- Article
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1536, doi. 10.1111/bjh.19330
- By:
- Publication type:
- Article
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 6, p. 1116, doi. 10.1111/bjh.18796
- By:
- Publication type:
- Article
Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study).
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. 175, doi. 10.1111/bjh.18486
- By:
- Publication type:
- Article
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 2, p. 393, doi. 10.1111/bjh.17654
- By:
- Publication type:
- Article
Molecular monitoring of patients with ETV6‐PDGFRB rearrangement: Implications for therapeutic adaptation.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 1, p. 148, doi. 10.1111/bjh.14748
- By:
- Publication type:
- Article
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 1, p. 71, doi. 10.1111/bjh.14022
- By:
- Publication type:
- Article
Safety and efficacy of pulsed imatinib with or without G- CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 5, p. 674, doi. 10.1111/bjh.12532
- By:
- Publication type:
- Article
The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 5, p. 394, doi. 10.3816/CLML.2010.n.073
- By:
- Publication type:
- Article
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 10, p. 1637, doi. 10.1002/cncr.29240
- By:
- Publication type:
- Article
Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 20, p. 5183, doi. 10.1002/cncr.27481
- By:
- Publication type:
- Article
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Expanding Nilotinib Access in Clinical Trials (ENACT).
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 1, p. 118, doi. 10.1002/cncr.26249
- By:
- Publication type:
- Article
New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia.
- Published in:
- Leukemia Research & Treatment, 2013, p. 1, doi. 10.1155/2013/756703
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
- Published in:
- Annals of Internal Medicine, 2018, v. 168, n. 7, p. 461, doi. 10.7326/M17-1094
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
- Published in:
- 2019
- By:
- Publication type:
- journal article